tiprankstipranks
Trending News
More News >
Protagonist Therapeutics (PTGX)
NASDAQ:PTGX
US Market

Protagonist Therapeutics (PTGX) Income Statement

Compare
728 Followers

Protagonist Therapeutics Income Statement

Last quarter (Q3 2025), Protagonist Therapeutics's total revenue was $4.71M, an increase of 0.79% from the same quarter last year. In Q3, Protagonist Therapeutics's net income was $-39.34M. See Protagonist Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 434.43M$ 60.00M$ 26.58M$ 27.36M$ 28.63M
Gross Profit
$ 434.43M$ 60.00M$ 26.58M$ 27.36M$ 28.63M
Operating Expenses
$ 181.59M$ 153.65M$ 157.95M$ 153.20M$ 93.14M
Depreciation and Amortization
$ 826.00K$ 3.31M$ 3.37M$ 2.77M$ 948.00K
EBITDA
$ 253.67M$ -90.34M$ -128.00M$ -123.07M$ -63.57M
Operating Income
$ 252.84M$ -93.65M$ -131.37M$ -125.84M$ -64.52M
Other Income/Expenses
$ 26.57M$ 14.70M$ 3.98M$ 294.00K$ -329.00K
Pretax Income
$ 279.41M$ -78.95M$ -127.39M$ -125.55M$ -64.84M
Net Income
$ 275.19M$ -78.95M$ -127.39M$ -125.55M$ -66.15M
Per Share Metrics
Basic EPS
$ 4.47$ -1.39$ -2.52$ -2.65$ -1.92
Diluted EPS
$ 4.23$ -1.39$ -2.52$ -2.65$ -1.92
Weighted Average Shares Outstanding
61.57M 56.76M 49.04M 46.32M 34.40M
Weighted Average Shares Outstanding (Diluted)
65.08M 56.76M 49.04M 46.32M 34.40M
Currency in USD

Protagonist Therapeutics Earnings and Revenue History